Based on the rationale that TNF-α plays a central role in the regulation of RA-related molecules, anti-TNF drugs were the first biological agents to be introduced for treatment of RA, starting with infliximab, a chimeric anti-TNF-α monoclonal antibody, in 1999 [1,17]. Here, TNF is linked to rheumatoid arthritis.